Zogenix Announces Agreement to Refinance Debt, Further Increasing Company’s Expected 2017 Cash Balance
- Interest-only repayment provision results in
The new loan proceeds will increase the total amount of term loan principal outstanding to
Additional details of the term loan facility are outlined in the Company's Current Report on Form 8-K filed with the
For more information, visit www.zogenix.com.
About Dravet Syndrome
Dravet syndrome (also known as Severe Myoclonic Epilepsy of Infancy) is a rare, severe and therapy-resistant form of epilepsy most often caused by an identifiable gene defect that results in abnormal functioning of a sodium channel in the brain. Children with Dravet syndrome experience severe, long-lasting, fever-related seizures in the first year of life. Other seizures typically arise later, including myoclonus (involuntary muscle spasms) and status epilepticus (prolonged seizures), which often result in severe cognitive and developmental impairment. Episodes of status epilepticus require immediate emergency care and can be fatal.
Individuals with Dravet syndrome face a higher incidence of SUDEP (sudden unexplained death in epilepsy) and have associated conditions, which also require proper treatment and management. Children with Dravet syndrome do not outgrow this condition and it affects every aspect of their daily lives.
Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over
For more than 30 years,
Forward Looking Statements
Andrew McDonaldFounding Partner, LifeSci Advisors LLC646-597-6987 Andrew@lifesciadvisors.com